Ghrelin Receptor Agonist
ENTYCE® (capromorelin oral solution) is a ghrelin receptor agonist that mimics the effect of ghrelin (the “hunger hormone”). Like naturally occurring ghrelin, ENTYCE binds to specific cell receptors and affects signaling in the hypothalamus, causing the feeling of hunger.
Several studies demonstrating efficacy and safety in laboratory and client-owned dogs treated with ENTYCE have been conducted.1,2
1Zollers B, Huebner M, Armintrout G, Rausch-Derra LC, Rhodes L. Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin (ENTYCE®), a novel drug for stimulation of appetite [published online ahead of print September 25, 2016]. J Vet Pharmacol Ther. doi: 10.1111/jvp.12358.
2Zollers B, Wofford JA, Heinen E, Huebner M, Rhodes L. A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite. J Vet Intern Med. 2016;30(6):1851-1857.
ENTYCE Mechanism of Action Video
ENTYCE® (capromorelin oral solution)
For Appetite Stimulation in Dogs
Reduced appetite is often the first sign of illness in a dog and in some cases may be the only sign. Weight loss and decreased muscle mass from inappetence can lead to a poor quality of life.
While diagnosing and developing a plan for treating the underlying cause of their inappetence, it’s important to get a dog eating, unless contraindicated.
The control of hunger and appetite is a complicated interaction of hormones, nutrients, and neuronal signals that come primarily from the GI tract and adipose tissue and converge on the hypothalamus.
Ghrelin travels through the blood stream to the hypothalamus where it binds to specific receptors, resulting in appetite-stimulating neuronal signals. As ghrelin binds, it activates appetite-stimulating neuronal signals and triggers the desire to eat. Ghrelin binding also initiates the release of growth hormone, which in turn increases IGF-1 production.
ENTYCE® (capromorelin oral solution) has been developed specifically to address inappetence in dogs. Capromorelin mimics the naturally occurring hormone, ghrelin, and acts to stimulate the feeling of hunger.
Capromorelin is a ghrelin receptor agonist that is administered orally and absorbed in the stomach.
As a mimetic of ghrelin, capromorelin also binds to and affects the same receptors in the brain which stimulate hunger and triggers the dog’s desire to eat. Administering ENTYCE (capromorelin oral solution) was shown to be clinically effective in a variety of clinical presentations.
ENTYCE (capromorelin oral solution) is FDA-approved to stimulate appetite in dogs and is used to treat inappetence in dogs with a variety of clinical conditions.
IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.
Other therapeutics from Aratana
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls post-op pain with one dose at the source for up to 72 hours following canine cranial cruciate ligament surgery or feline onychectomy to help patients recover comfortably.
DOG INDICATION: For single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs only. Do not use in dogs younger than 5 months of age, that are pregnant, lactating or intended for breeding. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.
CAT INDICATION: For use as a peripheral nerve block to provide regional post-operative analgesia following onychectomy in cats.
IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use as a peripheral nerve block in cats only. Do not use in cats younger than 5 months of age, that are pregnant, lactating, or intended for breeding. Do not administer by intravenous or intra-arterial injection. Adverse reactions in cats may include elevated body temperature, infection or chewing/licking at the surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.